Teva Pharm Stock Price, News & Analysis

Teva Pharmaceutical reported strong financial results for Q4 and FY 2024, marking its second consecutive year of growth. The company achieved revenues of $16.5 billion in 2024, representing a 6% increase in local currency terms compared to 2023.

Key highlights include AUSTEDO exceeding $1.6 billion in revenues, AJOVY reaching $507 million (18% growth), and UZEDY achieving $117 million. The generics business showed robust growth across all segments: 15% in the U.S., 6% in Europe, and 15% in International Markets.

For 2025, Teva projects revenues of $16.8-$17.4 billion, with non-GAAP EPS of $2.35-$2.65. The company continues to execute its Pivot to Growth strategy, expanding its biosimilar pipeline to 18 assets and advancing key innovative products. However, the company reported a GAAP loss per share of $1.45 for FY 2024 and $0.19 for Q4 2024.

Alvotech and Teva Pharmaceuticals announced that the FDA has accepted for review Biologics License Applications (BLA) for AVT05, their proposed biosimilar to Simponi® and Simponi Aria® (golimumab). These are the first U.S. BLA filing acceptances for a golimumab biosimilar candidate, with FDA review expected to complete in Q4 2025.

The announcement follows positive top-line results from a confirmatory clinical study in April 2024 comparing AVT05 with Simponi® in rheumatoid arthritis patients, and successful pharmacokinetic study results in November 2023. This development is part of Alvotech and Teva's strategic partnership, which now includes nine biosimilar products. The partnership has already achieved FDA approval for two other biosimilars: SIMLANDI® (adalimumab-ryvk) in February 2024 and SELARSDITM (ustekinumab-aekn) in April 2024.

Teva Pharmaceuticals has announced a strategic collaboration with Klinge Biopharma and Formycon AG for the semi-exclusive commercialization of FYB203, a biosimilar candidate to Eylea® (aflibercept) in Europe (excluding Italy) and Israel. The product will be marketed under the brand name AHZANTIVE®, pending regulatory approval.

The collaboration leverages Teva's commercial experience in biosimilars and distribution network across Europe, combined with Formycon's expertise in biosimilar development. Under the agreement, Teva will lead commercialization efforts, while Klinge will receive milestone payments and revenue sharing.

The EMA's CHMP issued a positive recommendation for FYB203 in November 2024, with European Commission's decision expected in January 2025. The FDA has already approved the biosimilar in June 2024. Eylea®, used to treat neovascular age-related macular degeneration and other retinal diseases, generated global sales of approximately $9 billion in 2023, including $2.9 billion in the European market.

Samsung Bioepis and Teva have announced a strategic partnership for the commercialization of EPYSQLI® (eculizumab-aagh) in the United States. Under the agreement, Samsung Bioepis will handle development, regulatory registration, manufacturing, and supply, while Teva will manage U.S. commercialization.

EPYSQLI, a biosimilar to Soliris®, is approved for treating rare diseases including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG). The FDA approved EPYSQLI in July 2024 for PNH and aHUS, with gMG indication added in November 2024.

The partnership aligns with Teva's Pivot to Growth strategy and expands its biosimilar portfolio to 18 assets. EPYSQLI is already commercially available in Europe since July 2023 and Korea since April 2024.

Teva Pharmaceutical Industries (NYSE and TASE: TEVA) has announced that their President and CEO, Richard Francis, will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Monday, January 13, 2025, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time).

Interested parties can access a live webcast of the presentation through Teva's Investor Relations website. An archived version will be made available within 24 hours after the live discussion concludes.

Teva Pharmaceutical Industries (NYSE and TASE: TEVA) has announced it will release its fourth quarter and full year 2024 financial results along with 2025 financial guidance on Wednesday, January 29, 2025, at 7:00 a.m. ET. The company will host a conference call and live webcast at 8:00 a.m. ET on the same day. Participants need to register in advance to obtain call-in details. A webcast replay will be available within 24 hours after the call on Teva's investor relations website.

Teva Pharmaceuticals and Sanofi announced positive Phase 2b results for duvakitug, their joint inflammatory bowel disease (IBD) treatment. The RELIEVE UCCD study met primary endpoints for both ulcerative colitis (UC) and Crohn's disease (CD). In UC patients, duvakitug achieved clinical remission rates of 36.2% (low-dose) and 47.8% (high-dose) compared to 20.45% for placebo. For CD patients, endoscopic response rates were 26.1% (low-dose) and 47.8% (high-dose) versus 13.0% for placebo.

The treatment showed consistent effects across subgroups and was generally well tolerated, with adverse events equally distributed between treatment and placebo groups (50% vs 50%). These results represent the highest achieved with any TL1A monoclonal antibody. Both companies plan to initiate Phase 3 development pending regulatory discussions.

Teva Pharmaceuticals has launched a new patient access program in partnership with Direct Relief to provide free inhalers to uninsured patients in the United States. The program, running for a minimum of three years, will supply two generic inhaler products: generic versions of AirDuo®RespiClick® (maintenance inhaler) and ProAir® HFA (rescue inhaler).

The initiative aims to address accessibility issues for uninsured patients, as while 93% of Teva's inhaler medicines are generic products with lower prices for insured patients, uninsured individuals still face affordability challenges. Teva will donate the inhalers to Direct Relief for distribution through their network of free and charitable clinics. Additionally, Teva will provide a cash donation to cover program administration costs.

Teva Pharmaceutical Industries has announced an agreement to sell its Teva-Takeda business venture in Japan to JKI Co., , a company established by private equity firm J-Will Partners. The divestment aligns with Teva's Pivot to Growth strategy and will allow the company to focus on its innovative medicines business in the Japanese market.

The transaction involves the transfer of all shares of Teva Takeda Pharma and its subsidiary Teva Takeda Yakuhin The deal is expected to complete by April 1, 2025, subject to regulatory approvals. All employees of the business venture will retain their positions under the agreement terms.